Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Butyrate enemas have been reported to be effective in ulcerative colitis. However, long-term use is difficult because of the troublesome procedure and the unpleasant smell. We therefore investigated the effects of the oral administration of Clostridium butyricum M588 (CBM588), an enterobacterium producing butyrate, in dextran sodium sulfate (DSS)-induced colitis in rats. First, we confirmed the effects of pre-treatment with a butyrate enema on DSS colitis. We then studied the efficacy of oral administration of CBM588 which was started 1 week prior to the induction of DSS colitis. In the CBM588 group, the ulcer index and myeloperoxidase (MPO) activity in the distal colon were significantly lower than in the control group. Proliferating cell nuclear antigen (PCNA) immuno-positive cells were increased around the ulcer in the CBM588 group. In regard to the contents of the cecum and colon, the proportions of Lactobacillus and Eubacterium were increased in the cecum in the CBM588 group. Further, there were significant increases of n-butyrate, propionate, and acetate concentrations in the cecum in the CBM588 group. These results indicated that the oral administration of CBM588 alleviated DSS-induced colitis, and may be useful instead of butyrate enema.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Like butyrate, propionate is also a short chain fatty acid that has been shown to have an anticancer effect: previous in vivo studies assessing CBM588 have demonstrated upregulation of this metabolite27,28.”
From Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial (2022) · cites this paper as [28]
In the citing paper
“previous in vivo studies assessing CBM588 have demonstrated upregulation of this metabolite27,28.”
From Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial (2022) · cites this paper as [28]
Citations
Cites
Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity
Krawisz, J. E., Sharon, P., & Stenson, W. F. (1984) · Gastroenterology · doi:10.1016/0016-5085(84)90202-6 · Cited by 1,758
Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis
Scheppach, W., Sommer, H., Kirchner, T., Paganelli, G.-M., Bartram, P., Christl, S., Richter, F., Dusel, G., & Kasper, H. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91094-k · Cited by 741
THE COLONIC EPITHELIUM IN ULCERATIVE COLITIS: AN ENERGY-DEFICIENCY DISEASE?
Roediger, W. E. W. (1980) · The Lancet · doi:10.1016/s0140-6736(80)91934-0 · Cited by 719
Sakata, T. (1987) · British Journal of Nutrition · doi:10.1079/bjn19870073 · Cited by 653
Butyrate production from dietary fibre and protection against large bowel cancer in a rat model.
McIntyre, A., Gibson, P. R., & Young, G. P. (1993) · Gut · doi:10.1136/gut.34.3.386 · Cited by 555
Hague, A., Elder, D. J. E., Hicks, D. J., & Paraskeva, C. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600322 · Cited by 412
Role of short-chain fatty acids in the prevention of colorectal cancer
Scheppach, W., Bartram, H. P., & Richter, F. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00165-f · Cited by 349
Stimulation of Intestinal Mucosal Growth with Intracolonic Infusion of Short‐Chain Fatty Acids
Kripke, S. A., Fox, A. D., Berman, J. M., Settle, R. G., & Rombeau, J. L. (1989) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607189013002109 · Cited by 336
Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat.
Butzner, J. D., Parmar, R., Bell, C. J., & Dalal, V (1996) · Gut · doi:10.1136/gut.38.4.568 · Cited by 213
Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas.
Steinhart, A. H., Brzezinski, A., & Baker, J. (1994) · PubMed · Cited by 137
Cited by
Tedelind, S., Westberg, F., Kjerrulf, M., & Vidal, A. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i20.2826 · Cited by 853
From the gut to the peripheral tissues: the multiple effects of butyrate
Guilloteau, P., Martin, L., Eeckhaut, V., Ducatelle, R., Zabielski, R., & Van Immerseel, F. (2010) · Nutrition Research Reviews · doi:10.1017/s0954422410000247 · Cited by 806
“Many studies have demonstrated that delivery of butyrate through local enema or diet results in a protective or therapeutic effect against inflammatory bowel diseases((170,171)).”
Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01694-6 · Cited by 515
Larrosa, M., González-Sarrías, A., Yáñez-Gascón, M. J., Selma, M. V., Azorín-Ortuño, M., Toti, S., Tomás-Barberán, F., Dolara, P., & Espín, J. C. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.04.012 · Cited by 504
“In fact, it has also been confirmed that butyrate has anti-inflammatory actions through its suppression of the inflammatory cytokine cascade [35].”
BackgroundEnhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate†
Lewis, K., Lutgendorff, F., Phan, V., Söderholm, J. D., Sherman, P. M., & McKay, D. M. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21177 · Cited by 335
Metadata
- Authors
- Okamoto, T., Sasaki, M., Tsujikawa, T., Fujiyama, Y., Bamba, T., & Kusunoki, M.
- Affiliations
- Shiga University of Medical Science (JP)
- Miyarisan Pharmaceutical Co., Ltd. (Japan) (JP)
- Venue
- Journal of Gastroenterology
- Published
- 2000-05-08
- Volume
- 35
- Issue
- 5
- Pages
- 341-346
- ISSN
- 0944-1174 (ISSN-L)
- 1435-5922
- OpenAlex
- W2023882748
- Cited by
- 91
- References
- 16
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 6 · 2014: 4 · 2013: 7
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- DSS-induced colitis, ulcerative colitis, oral administration, short-chain fatty acids, butyrate, Lactobacillus, Eubacterium, myeloperoxidase, proliferating cell nuclear antigen, cecal microbiota, prophylaxis
- MeSH terms
- Acetates, Administration, Oral, Animals, Butyrates, Clostridium, Colitis, Ulcerative, Enema, Male, Peroxidase, Propionates, Dextran Sulfate, Rats, Sprague-Dawley, Proliferating Cell Nuclear Antigen, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.